Hematology · Cardiology ·
Review examines light-chain testing in systemic amyloidoses
This review surveys laboratory methods for detecting and monitoring amyloidogenic immunoglobulin light chains in systemic amyloidoses. It also discusses approaches to distinguish pathogenic light chains from incidental monoclonal clones, including in patients being evaluated for transthyretin amyloidosis.
- Reviews laboratory methods for light-chain detection and monitoring.
- Discusses measurable residual disease assessment and treatment response.
- Highlights challenges distinguishing AL from transthyretin amyloidosis.
- Standardized relapse definitions remain an unmet need.
Immunoglobulin light chains arise across a spectrum of B-cell clonal disorders, but in AL amyloidosis a monoclonal light chain causes organ damage. This review summarizes current and emerging laboratory approaches for detecting amyloidogenic light chains, assessing hematologic response and identifying relapse. It discusses mass spectrometry, flow cytometry and next-generation sequencing for deep response assessment and measurable residual disease detection.
The authors also describe proposed ways to distinguish amyloidogenic from apparently “innocent” light chains, including biomarkers of early organ damage and light-chain features such as N-glycosylation, germline gene usage and reduced stability. These approaches may help identify risk among patients with monoclonal gammopathies and support the differential diagnosis of non-AL amyloidoses, particularly transthyretin cardiac amyloidosis, where a coexisting light-chain-producing clone can complicate assessment.
The review highlights the need for sensitive detection and quantitative monitoring, while noting that standardized definitions of relapse remain an unmet need. It synthesizes laboratory strategies and future directions rather than reporting a new clinical study or establishing a specific testing algorithm.
In practice
For clinicians assessing suspected systemic amyloidosis, the review underscores the importance of detecting a pathogenic monoclonal light chain and distinguishing AL amyloidosis from transthyretin amyloidosis, particularly when a light-chain-producing clone is also present. It describes mass spectrometry, flow cytometry and sequencing approaches for response and residual-disease assessment, but does not establish a specific testing algorithm or standardized relapse definition. As a review of current and emerging methods, it supports the diagnostic relevance of these tools but does not itself provide evidence for a change in practice.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Blood: Detection, Monitoring, and Discrimination of Amyloidogenic vs Innocent Light Chains in Systemic Amyloidoses ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.